Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.

A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it ...

Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.5% in the afternoon session after the U.S.

Lawsuit alleges anti-competitive conduct designed to suppress lawful compounding pharmaceuticals and limit patient choice ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

Pharma giant AbbVie reveals plans to expand its presence in the obesity drug market through pipeline development and ...

The FDA delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists ...

The company’s latest preview report projects a guarded rebound for biopharma, as investor confidence returns and M&A activity ...

Eli Lilly (LLY) stock slips as the FDA decision on the company's obesity pill orforglipron is now due in April, which ...